



## CERTIFICATE OF ANALYSIS No.: 2022-10737

**CLIENT** 

Nordic Med Can AB, Eriksgatan 4 52135 Falköping, Sweden

SAMPLE \* CB3-spray





Sample condition:	SUITABLE	Work order:	2022-107178	Sample received:	19/12/2022
Sample ID:	2251011	Analysis ID:	2022_286	Start of analysis:	20/12/2022
Sample type:	Viscous liquid	Method ID:	PHL_RPC_12C	End of analysis:	21/12/2022
Batch No.: *		Method SOP:	MET-LAB-003-02	Analyst:	Domen Lavriha

<sup>\*</sup> Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	-Cannabidivarin	<loq< th=""><th>n/a</th><th></th></loq<>	n/a	
CBDA	-Cannabidiolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBGA	-Cannabigerolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBG	-Cannabigerol	5.03	0.35	
CBD	-Cannabidiol	5.10	0.25	
THCV	-Tetrahydrocannabivarin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBN	-Cannabinol	5.05	0.25	
∆ <sup>9</sup> -THC	$-\Delta$ -9-Tetrahydrocannabinol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
∆ <sup>8</sup> -THC	-∆-8-Tetrahydrocannabinol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBL	-Cannabicyclol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBC	-Cannabichromene	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
∆ <sup>9</sup> -THCA	$-\Delta$ -9-Tetrahydrocannabinolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBE	–Cannabielsoin	<loq #<="" td=""><td>n/a</td><td></td></loq>	n/a	
CBV	-Cannabivarin	<loq #<="" td=""><td>n/a</td><td></td></loq>	n/a	
CBCA	-Cannabichromenic acid	<loq #<="" td=""><td>n/a</td><td></td></loq>	n/a	
CBT	-Cannabicitran	<loq #<="" td=""><td>n/a</td><td></td></loq>	n/a	

 $\underline{\text{Units and abbreviations:}} \ \% \ \text{w/w} = \text{weight percent,} \ < \text{LOQ} \ = \text{below the limit of quantitation (0.03 \% \ w/w), ND} = \text{not detected, n/a} = \text{not available.}$ 

The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98–3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:	Approved by:	Authorized by:
21/12/2022	Aley	Jany Fat
	mag.Janja Ahej	dr. Boštjan Jančar
	Analytical Laboratory Manager	Chief Technology Officer
End of Certificate		